Diplatin, a novel water-soluble platinum complex, inhibits lung cancer growth via augmentation of Fas-mediated apoptosis

This publication has 27 references indexed in Scilit:

• Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance
  Frontiers in Pharmacology, 2019
• Effects of Early Integrated Palliative Care on Caregivers of Patients with Lung and Gastrointestinal Cancer: A Randomized Clinical Trial
  The Oncologist, 2017
• Cisplatin resistance and opportunities for precision medicine
  Pharmacological Research, 2016
• Tacrolimus and the Risk of Solid Cancers After Liver Transplant: A Dose Effect Relationship
  American Journal of Transplantation, 2015
• Glaucocalyxin A Activates FasL and Induces Apoptosis Through Activation of the JNK Pathway in Human Breast Cancer Cells
  Asian Pacific Journal of Cancer Prevention, 2013
• Highly water-soluble platinum(ii) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties
  Chemical Communications, 2013
• Molecular mechanisms of cisplatin resistance in bladder cancer
  Expert Review of Anticancer Therapy, 2012
• Lung Cancer: Epidemiology, Etiology, and Prevention
  Clinics in Chest Medicine, 2011
• Cisplatin: a review of toxicities and therapeutic applications
  Veterinary and Comparative Oncology, 2008
• Long‐term activation of SAPK/JNK, p38 kinase and fas‐L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance
  International Journal of Cancer, 2004